Advertisement
Retraction
Open Access | 10.1172/JCI198611
Find articles by Feng, H. in: PubMed | Google Scholar
Find articles by Hu, B. in: PubMed | Google Scholar
Find articles by Liu, K. in: PubMed | Google Scholar
Find articles by Li, Y. in: PubMed | Google Scholar
Find articles by
Lu, X.
in:
PubMed
|
Google Scholar
|
Find articles by Cheng, T. in: PubMed | Google Scholar
Find articles by Yiin, J. in: PubMed | Google Scholar
Find articles by Lu, S. in: PubMed | Google Scholar
Find articles by Keezer, S. in: PubMed | Google Scholar
Find articles by Fenton, T. in: PubMed | Google Scholar
Find articles by Furnari, F. in: PubMed | Google Scholar
Find articles by Hamilton, R. in: PubMed | Google Scholar
Find articles by Vuori, K. in: PubMed | Google Scholar
Find articles by Sarkaria, J. in: PubMed | Google Scholar
Find articles by Nagane, M. in: PubMed | Google Scholar
Find articles by Nishikawa, R. in: PubMed | Google Scholar
Find articles by Cavenee, W. in: PubMed | Google Scholar
Find articles by Cheng, S. in: PubMed | Google Scholar
Published September 16, 2025 - More info
Two hallmarks of glioblastoma multiforme, the most common malignant brain cancer in humans, are aggressive growth and the ability of single glioma cells to disperse throughout the brain. These characteristics render tumors resistant to current therapies and account for the poor prognosis of patients. Although it is known that oncogenic signaling caused by overexpression of genes such as PDGFRA is responsible for robust glioma growth and cell infiltration, the mechanisms underlying glioblastoma malignancy remain largely elusive. Here, we report that PDGFRα signaling in glioblastomas leads to Src-dependent phosphorylation of the guanine nucleotide exchange factor Dock180 at tyrosine 1811 (Dock180Y1811) that results in activation of the GTPase Rac1 and subsequent cell growth and invasion. In human glioma cells, knockdown of Dock180 and reversion with an RNAi-resistant Dock180Y1811F abrogated, whereas an RNAi-resistant Dock180WT rescued, PDGFRα-promoted glioma growth, survival, and invasion. Phosphorylation of Dock180Y1811 enhanced its association with CrkII and p130Cas, causing activation of Rac1 and consequent cell motility. Dock180 also associated with PDGFRα to promote cell migration. Finally, phosphorylated Dock180Y1811 was detected in clinical samples of gliomas and various types of human cancers, and coexpression of phosphorylated Dock180Y1811, phosphorylated SrcY418, and PDGFRα was predictive of extremely poor prognosis of patients with gliomas. Taken together, our findings provide insight into PDGFRα-stimulated gliomagenesis and suggest that phosphorylated Dock180Y1811 contributes to activation of Rac1 in human cancers with PDGFRA amplification.
Haizhong Feng, Bo Hu, Kun-Wei Liu, Yanxin Li, Xinghua Lu, Tao Cheng, Jia-Jean Yiin, Songjian Lu, Susan Keezer, Tim Fenton, Frank B. Furnari, Ronald L. Hamilton, Kristiina Vuori, Jann N. Sarkaria, Motoo Nagane, Ryo Nishikawa, Webster K. Cavenee, Shi-Yuan Cheng
Original citation: J Clin Invest. 2011;121(12):4670–4684. https://doi.org/10.1172/JCI58559
Citation for this retraction: J Clin Invest. 2025;135(18):e198611. https://doi.org/10.1172/JCI198611
Errors were recently identified in Figure 4, B, I, and K, and Supplemental Figure 5, J and K. Although the authors have indicated that original source data support the findings in these figure panels, the Editors are retracting the article due to the number of errors made.
Webster K. Cavenee agrees with the retraction. Shi-Yuan Cheng and Motoo Nagane dissent from the Journal’s decision to retract. The remaining authors abstained from commenting or could not be reached.